JAPANESE pharmaceutical giant Takeda has announced the enrolment of over 20,000 children and adolescents in a global Phase 3 trial of the company's new vaccine candidate for dengue fever.
The Tetravalent Immunisation Against Dengue Efficacy Study (TIDES) will evaluate the efficacy of two doses of candidate vaccine TAK-003 administered three months apart, to protect against all four strains of dengue virus regardless of previous exposure.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Apr 17
